BioNexus Gene Lab Announce The Successful Co-Investment By The Securities Commission Of Malaysia Into Ascension Innovation Sdn Bhd
BioNexus Gene Lab Announce The Successful Co-Investment By The Securities Commission Of Malaysia Into Ascension Innovation Sdn Bhd
BioNexus Gene Lab Corp. (NASDAQ:BGLC), an emerging leader in genomic diagnostics and personalized medicine, is pleased to announce the successful co-investment by the Securities Commission of Malaysia under its Malaysia Co-Investment Fund (MyCIF), into Ascension Innovation Sdn Bhd (AISB). This co-investment, alongside BGLC's recent investment, the first under its Environmental & Social Impact (ESI) Scheme shows confidence in the strategic direction and potential of AISB.
BioNexus Gene Lab corp.（纳斯达克：BGLC）是基因组诊断和个性化医学领域新兴领导者，高兴地宣布马来西亚证券委员会在其马来西亚共同投资基金（MyCIF）下对Ascension Innovation私人有限公司（AISB）进行成功共同投资。这次共同投资与BGLC最近的首次环保和社会影响（ESI）计划投资同时进行，显示了对AISB战略方向和潜力的信心。
AISB, a pioneering healthcare technology company, has become the first issuer to receive investment under the Environmental & Social Impact (ESI) scheme, part of the broader MyCIF initiative. This scheme, designed to support small and medium enterprises (MSMEs) with impactful solutions, aligns perfectly with AISB's mission to revolutionize healthcare through innovative, sustainable practices.
AISB是一家开拓性的医疗科技公司，成为首家在环保和社会影响（ESI）计划下获得投资的发行人，该计划是马来西亚共同投资基金（MyCIF）倡议的一部分。该计划旨在支持具有影响力解决方案的中小企业（MSMEs），与AISB通过创新可持续实践改革医疗保健的使命完美契合。
译文内容由第三方软件翻译。
